Journal
IMMUNOTHERAPY
Volume 9, Issue 16, Pages 1359-1372Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0134
Keywords
cancer; dendritic cell; epigenetic; exhaustion; gene expression; histone deacetylase; histone deacetylase inhibitor; immunogenic; T-cell; tumor immunotherapy
Categories
Funding
- Breast Cancer Research Foundation of Alabama (BCRFA)
- UAB Comprehensive Cancer Center support grant [P30CA013148]
- NIH [RO1CA216234]
Ask authors/readers for more resources
Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dendritic cell activation and migration, antigen uptake and presentation, T-cell activation and differentiation and the enactment of antitumor effector functions within the tumor microenvironment. In particular, we will discuss how various inhibitors have different effects depending on cellular activation, experimental design and specific histone deacetylases being targeted - and how these changes impact the outcome of an antitumor immune response. At last, we consider the impact these inhibitors may have on T-cell exhaustion and implications for combination with other immunomodulating therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available